A bivalent porcine circovirus type 2 (PCV2), PCV2a-PCV2b, vaccine offers biologically superior protection compared to monovalent PCV2 vaccines

Table 6 Summary of back-transformed LS means PCV2 copies/5 µL in feces (fecal shedding) by qPCR by treatment and study day for studies B and C

Study	Treatment Group (T)	Day of Study								% pigs ever positive post-challenge
Study	Treatment Group (T)	− 1	21	24	28 or 29	31	35	38	42	% pigs ever positive post-challenge
B	T01	0	0	7	2.01E + 02	6.45E + 03	2.46E + 04	2.28E + 04	9.62E + 03	100
B	T02	0	0	14.0	1.0*	14.0*	8.0*	3.0*	11.0*	68.2**
B	T03	0	0	7.0	0*	1.0*	12.0*	4.0*	1.0*	47.8**
C	T01	0	0	2.0	26	9.99E + 04	1.95E + 04	3.47E + 03	7.95E + 03	100
C	T02	0	0	1.0	5.0	1.33E + 03**	2.20E + 02**	1.40E + 02**	14.0**	90.5^
C	T03	0	0	1.0	3.0	3.71E + 02**	2.15E + 02**	5.30E + 02**	14.0**	86.4^

Value is significantly different from T01 saline controls (*P ≤ 0.0003, ** P ≤ 0.05) within a column (Day of Study) by Study. ^Value is not significantly different from T01 (P ≥ 0.1). Study Day 0 corresponded to the day of vaccination.

ISSN: 1297-9716